A detailed history of Allworth Financial LP transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Allworth Financial LP holds 293 shares of ZNTL stock, worth $972. This represents 0.0% of its overall portfolio holdings.

Number of Shares
293
Previous 293 -0.0%
Holding current value
$972
Previous $1,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 23, 2024

BUY
$4.09 - $16.13 $1,198 - $4,726
293 New
293 $1,000
Q3 2023

Oct 31, 2023

SELL
$19.63 - $28.29 $19 - $28
-1 Reduced 12.5%
7 $0
Q2 2023

Jul 18, 2023

BUY
$17.41 - $30.05 $139 - $240
8 New
8 $0
Q4 2022

Jan 13, 2023

BUY
$18.07 - $25.6 $36 - $51
2 Added 28.57%
9 $0
Q2 2022

Jul 13, 2022

BUY
$17.91 - $52.25 $125 - $365
7 New
7 $0

Others Institutions Holding ZNTL

About Zentalis Pharmaceuticals, Inc.


  • Ticker ZNTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,983,600
  • Market Cap $189M
  • Description
  • Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...
More about ZNTL
Track This Portfolio

Track Allworth Financial LP Portfolio

Follow Allworth Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allworth Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Allworth Financial LP with notifications on news.